Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$146.07
+0.2%
$151.09
$143.50
$218.88
$18.40B0.39788,867 shs542,714 shs
Nikola Co. stock logo
NKLA
Nikola
$0.64
$0.75
$0.52
$3.71
$848.51M1.9996.96 million shs46.69 million shs
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
$40.40
+3.4%
$44.76
$37.78
$95.02
$2.61B0.111.01 million shs1.19 million shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
+0.19%-0.44%-0.30%-21.13%-28.67%
Nikola Co. stock logo
NKLA
Nikola
+0.76%-4.48%-4.08%-8.30%-22.54%
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
+3.38%+0.25%-13.68%-42.28%-56.37%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
4.3877 of 5 stars
4.33.00.04.31.81.70.6
Nikola Co. stock logo
NKLA
Nikola
2.1688 of 5 stars
3.14.00.00.02.90.80.6
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
4.9504 of 5 stars
4.05.00.03.82.33.32.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.56
Moderate Buy$216.1247.95% Upside
Nikola Co. stock logo
NKLA
Nikola
2.25
Hold$1.33109.87% Upside
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
2.00
Hold$61.6052.48% Upside

Current Analyst Ratings

Latest NKLA, QDEL, and ALNY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/9/2024
Nikola Co. stock logo
NKLA
Nikola
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoveragePeer Perform
4/8/2024
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
3/27/2024
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$234.00
3/5/2024
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$395.00
3/5/2024
Nikola Co. stock logo
NKLA
Nikola
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.00
3/4/2024
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Sell$70.00 ➝ $42.00
2/20/2024
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$165.00
2/20/2024
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$235.00
2/16/2024
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$171.00 ➝ $161.00
2/16/2024
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$237.00 ➝ $227.00
2/16/2024
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$250.00 ➝ $225.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$1.83B10.06N/AN/A($1.76) per share-82.99
Nikola Co. stock logo
NKLA
Nikola
$35.84M23.68N/AN/A$0.54 per share1.18
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
$3.00B0.90$11.35 per share3.56$74.92 per share0.54

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-$440.24M-$3.56N/AN/AN/A-24.08%N/A-12.18%5/2/2024 (Confirmed)
Nikola Co. stock logo
NKLA
Nikola
-$966.28M-$1.26N/AN/AN/AN/A-122.20%-61.92%5/7/2024 (Confirmed)
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
-$10.10M-$0.16N/A10.15N/A-0.34%5.54%3.21%5/8/2024 (Confirmed)

Latest NKLA, QDEL, and ALNY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
$0.54N/A-$0.54N/AN/AN/A  
5/7/2024N/A
Nikola Co. stock logo
NKLA
Nikola
-$0.10N/A+$0.10N/AN/AN/A  
5/2/2024N/A
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-$0.7540N/A+$0.7540N/AN/AN/A  
2/22/202412/31/2023
Nikola Co. stock logo
NKLA
Nikola
-$0.17-$0.12+$0.05-$0.10$14.52 million$11.53 million    
2/15/2024Q4 23
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-$1.20-$1.10+$0.10-$1.10$439.38 million$439.72 million    
2/13/2024Q4 2023
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
$2.01$1.17-$0.84$2.24$796.91 million$742.60 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
Nikola Co. stock logo
NKLA
Nikola
N/AN/AN/AN/AN/A
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/A
3.08
2.99
Nikola Co. stock logo
NKLA
Nikola
0.37
2.20
1.96
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
0.45
1.57
0.88

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
Nikola Co. stock logo
NKLA
Nikola
37.38%
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
99.00%

Insider Ownership

CompanyInsider Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
1.50%
Nikola Co. stock logo
NKLA
Nikola
10.00%
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
1.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,100125.95 million124.06 millionOptionable
Nikola Co. stock logo
NKLA
Nikola
8701.34 billion1.20 billionOptionable
QuidelOrtho Co. stock logo
QDEL
QuidelOrtho
7,10066.88 million66.21 millionOptionable

NKLA, QDEL, and ALNY Headlines

SourceHeadline
Private Management Group Inc. Boosts Stock Position in QuidelOrtho Co. (NASDAQ:QDEL)Private Management Group Inc. Boosts Stock Position in QuidelOrtho Co. (NASDAQ:QDEL)
marketbeat.com - April 23 at 10:25 PM
Class Action Filed Against QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) - June 11, 2024 Deadline to Join - Contact Levi & KorsinskyClass Action Filed Against QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) - June 11, 2024 Deadline to Join - Contact Levi & Korsinsky
accesswire.com - April 23 at 9:35 PM
QDEL May 2024 50.000 callQDEL May 2024 50.000 call
uk.finance.yahoo.com - April 23 at 5:47 PM
QDEL May 2024 40.000 putQDEL May 2024 40.000 put
uk.finance.yahoo.com - April 23 at 5:47 PM
Lost Money on QuidelOrtho Corporation f/k/a Quidel Corporation(QDEL)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyLost Money on QuidelOrtho Corporation f/k/a Quidel Corporation(QDEL)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
accesswire.com - April 23 at 5:20 PM
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 11, 2024 in QuidelOrtho Lawsuit - QDELLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 11, 2024 in QuidelOrtho Lawsuit - QDEL
accesswire.com - April 23 at 5:20 PM
Investors in QuidelOrtho Corporation f/k/a Quidel Corporation Should Contact Levi & Korsinsky Before June 11, 2024 to Discuss Your Rights - QDELInvestors in QuidelOrtho Corporation f/k/a Quidel Corporation Should Contact Levi & Korsinsky Before June 11, 2024 to Discuss Your Rights - QDEL
accesswire.com - April 23 at 12:00 PM
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against QuidelOrtho Corporation and Encourages Investors with Losses to Contact the FirmINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against QuidelOrtho Corporation and Encourages Investors with Losses to Contact the Firm
prnewswire.com - April 23 at 11:15 AM
Contact Levi & Korsinsky by June 11, 2024 Deadline to Join Class Action Against QuidelOrtho Corporation f/k/a Quidel Corporation(QDEL)Contact Levi & Korsinsky by June 11, 2024 Deadline to Join Class Action Against QuidelOrtho Corporation f/k/a Quidel Corporation(QDEL)
accesswire.com - April 23 at 5:30 AM
QDEL LAWSUIT ALERT: Levi & Korsinsky Notifies QuidelOrtho Corporation f/k/a Quidel Corporation Investors of a Class Action Lawsuit and Upcoming DeadlineQDEL LAWSUIT ALERT: Levi & Korsinsky Notifies QuidelOrtho Corporation f/k/a Quidel Corporation Investors of a Class Action Lawsuit and Upcoming Deadline
accesswire.com - April 23 at 5:30 AM
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of QuidelOrtho Corporation f/k/a Quidel Corporation(QDEL) ShareholdersLevi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of QuidelOrtho Corporation f/k/a Quidel Corporation(QDEL) Shareholders
accesswire.com - April 22 at 6:30 PM
Lost Money on QuidelOrtho Corporation f/k/a Quidel Corporation(QDEL)? Join Class Action Suit Seeking Recovery – Contact Levi & KorsinskyLost Money on QuidelOrtho Corporation f/k/a Quidel Corporation(QDEL)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
accesswire.com - April 22 at 6:30 PM
Shareholders that lost money on QuidelOrtho Corporation f/k/a Quidel Corporation(QDEL) should contact Levi & Korsinsky about pending Class Action - QDELShareholders that lost money on QuidelOrtho Corporation f/k/a Quidel Corporation(QDEL) should contact Levi & Korsinsky about pending Class Action - QDEL
accesswire.com - April 22 at 4:00 PM
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the FirmSHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm
markets.businessinsider.com - April 22 at 3:37 PM
QuidelOrtho Corporation (QDEL) Investor Notice: Robbins LLP Reminds Stockholders of the QuidelOrtho Corporation Shareholder Class ActionQuidelOrtho Corporation (QDEL) Investor Notice: Robbins LLP Reminds Stockholders of the QuidelOrtho Corporation Shareholder Class Action
businesswire.com - April 22 at 2:58 PM
Class Action Filed Against QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) Seeking Recovery for Investors - Contact Levi & KorsinskyClass Action Filed Against QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) Seeking Recovery for Investors - Contact Levi & Korsinsky
accesswire.com - April 22 at 7:35 AM
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the FirmDEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm
accesswire.com - April 22 at 7:00 AM
QuidelOrtho Corporation f/k/a Quidel Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - QDELQuidelOrtho Corporation f/k/a Quidel Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - QDEL
accesswire.com - April 22 at 6:15 AM
Shareholders that lost money on QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) should contact Levi & Korsinsky about pending Class Action - QDELShareholders that lost money on QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) should contact Levi & Korsinsky about pending Class Action - QDEL
accesswire.com - April 22 at 6:15 AM
QDEL LAWSUIT ALERT: Levi & Korsinsky Notifies QuidelOrtho Corporation f/k/a Quidel Corporation Investors of a Class Action Lawsuit and Upcoming DeadlineQDEL LAWSUIT ALERT: Levi & Korsinsky Notifies QuidelOrtho Corporation f/k/a Quidel Corporation Investors of a Class Action Lawsuit and Upcoming Deadline
prnewswire.com - April 22 at 5:45 AM
Levi & Korsinsky Notifies QuidelOrtho Corporation f/k/a Quidel Corporation Investors of a Class Action Lawsuit and Upcoming Deadline - QDELLevi & Korsinsky Notifies QuidelOrtho Corporation f/k/a Quidel Corporation Investors of a Class Action Lawsuit and Upcoming Deadline - QDEL
accesswire.com - April 22 at 5:00 AM
QDEL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that QuidelOrtho Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!QDEL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that QuidelOrtho Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
prnewswire.com - April 22 at 4:00 AM
QuidelOrtho Corporation f/k/a Quidel Corporation Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 11, 2024 to Discuss Your Rights - QDELQuidelOrtho Corporation f/k/a Quidel Corporation Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 11, 2024 to Discuss Your Rights - QDEL
accesswire.com - April 22 at 2:30 AM
QuidelOrtho Co. Forecasted to Earn Q1 2024 Earnings of $0.24 Per Share (NASDAQ:QDEL)QuidelOrtho Co. Forecasted to Earn Q1 2024 Earnings of $0.24 Per Share (NASDAQ:QDEL)
americanbankingnews.com - April 22 at 1:20 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

NASDAQ:ALNY
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Nikola logo

Nikola

NASDAQ:NKLA
Nikola Corporation operates as a technology innovator and integrator that develops energy and transportation solutions in the United States and internationally. The company operates in truck and energy units. It commercializes battery electric vehicles (BEV) and hydrogen fuel cell electric vehicles (FCEV) to the trucking sector. In addition, it develops a network of hydrogen fueling stations; and offers BEV charging solutions for its FCEV and BEV customers, as well as other third-party customers. Further, its products include Nikola Tre Class 8 truck and the Nikola's Class 8 FCEV. Additionally, the company assembles, integrates, and commissions its vehicles in collaboration with its business partners and suppliers. Nikola Corporation founded in 2015 and is headquartered in Phoenix, Arizona.
QuidelOrtho logo

QuidelOrtho

NASDAQ:QDEL
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.